Gene:
HLA-B
major histocompatibility complex, class I, B

last updated 02/28/2014

CPIC Dosing Guideline for abacavir and HLA-B

Summary

In individuals with the HLA-B*57:01 variant allele ("HLA-B*57:01-positive"), abacavir is not recommended and should be considered only under exceptional circumstances.

There's more of this guideline. Read more.


last updated 10/17/2012

CPIC Dosing Guideline for allopurinol and HLA-B

Summary

Allopurinol is contraindicated in individuals with the HLA-B*58:01 variant allele ("HLA-B*58:01-positive") due to significantly increased risk of allopurinol-induced SCAR.

There's more of this guideline. Read more.




last updated 03/11/2014

Professional Society Guideline for carbamazepine and HLA-B

Summary

The Canadian Pharmacogenomics Network for Drug Safety (CPNDS) clinical recommendation group has published guidelines for the use of HLA-B*15:02 genotype when prescribing carbamazepine (CBZ). They recommend that carbamazepine not be prescribed for CBZ-naive patients who carry at least one HLA-B*15:02 allele.

There's more of this guideline. Read more.




PharmGKB gathers information regarding PGx on FDA drug labels from the FDA's "Table of Pharmacogenomic Biomarkers in Drug Labels", and from FDA-approved FDA and EMA-approved (European Medicines Agency) EMA labels brought to our attention. Excerpts from the label and downloadable highlighted label PDFs are manually curated by PharmGKB.

Please note that some drugs may have been removed from or added to the FDA's "Table of Pharmacogenomic Biomarkers in Drug Labels" without our knowledge. We periodically check the table for additions to this table and update PharmGKB accordingly.

There is currently no such list for European drug labels - we are working with the EMA to establish a list of European Public Assessment Reports (EPAR)s that contain PGx information. We are constructing this list by initially searching for drugs for which we have PGx-containing FDA drug labels - of these 44 EMA EPARs were identified and are being curated for pgx information.

We welcome any information regarding drug labels containing PGx information approved by the FDA, EMA or other Medicine Agencies around the world - please contact feedback.


last updated 10/25/2013

FDA Label for abacavir and HLA-B

This label is on the FDA Biomarker List
Genetic testing recommended

Summary

The FDA-approved label for abacavir recommends genetic testing for the HLA-B*5701 allele prior to initiating or reinitiating treatment with abacavir in patients of unknown HLA-B*5701 status, and due to a high risk of hypersensitivity reaction abacavir is not recommended in individuals carrying this allele.

There's more of this label. Read more.


last updated 10/25/2013

FDA Label for carbamazepine and HLA-B

This label is on the FDA Biomarker List
Genetic testing required

Summary

The FDA-approved label for carbamazepine (Tegretol) states that screening of patients with ancestry in genetically at-risk populations (patients of Asian descent) for the presence of the HLA-B*1502 allele should be carried out prior to initiating treatment with Tegretol due to a high risk of serious and sometimes fatal dematologic reactions. Patients positive for the HLA-B*1502 allele should not be treated with Tegretol, unless the benefit clearly outweighs the risk. Association with the HLA-A*3101 and the risk of developing hypersensitivity reactions to carbamazepine is also mentioned in the label, though testing for this allele is not required.

There's more of this label. Read more.


last updated 10/25/2013

FDA Label for phenytoin and HLA-B

This label is on the FDA Biomarker List
Actionable PGx

Summary

A strong association between the risk of developing SJS/TEN and the presence of HLA-B*1502, an inherited allelic variant of the HLA B gene, in patients using carbamazepine. Limited evidence suggests that HLAB*1502 may be a risk factor for the development of SJS/TEN in patients of Asian ancestry taking other antiepileptic drugs associated with SJS/TEN, including phenytoin. Consideration should be given to avoiding phenytoin as an alternative for carbamazepine in patients positive for HLA-B*1502.

There's more of this label. Read more.


European Medicines Agency (EMA) Label for abacavir and HLA-B

Genetic testing required

Summary

The EMA European Public Assessment Report (EPAR) states screening for the HLA-B*5701 allele should be carried out prior to initiating abacavir treatment and recommends screening in patients of unknown HLA-B*5701 allele status who are reinitiating treatment with abacavir. Due to a high risk of hypersensitivity reaction abacavir is not recommended in individuals carrying this allele.

There's more of this label. Read more.


Clinical Variants that meet the highest level of criteria, manually curated by PharmGKB, are shown below. Please follow the link in the "Position" column for more information about a particular variant. Each link in the "Position" column leads to the corresponding PharmGKB Variant Page. The Variant Page contains summary data, including PharmGKB manually curated information about variant-drug pairs based on individual PubMed publications. The PMIDs for these PubMed publications can be found on the Variant Page.

To see more Clinical Variants with lower levels of criteria, click the button at the bottom of the table.

Disclaimer: The PharmGKB's clinical annotations reflect expert consensus based on clinical evidence and peer-reviewed literature available at the time they are written and are intended only to assist clinicians in decision-making and to identify questions for further research. New evidence may have emerged since the time an annotation was submitted to the PharmGKB. The annotations are limited in scope and are not applicable to interventions or diseases that are not specifically identified.

The annotations do not account for individual variations among patients, and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It remains the responsibility of the health-care provider to determine the best course of treatment for a patient. Adherence to any guideline is voluntary, with the ultimate determination regarding its application to be made solely by the clinician and the patient. PharmGKB assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the PharmGKB clinical annotations, or for any errors or omissions.

? = Mouse-over for quick help

This is a non-comprehensive list of genetic tests with pharmacogenetics relevance, typically submitted by the manufacturer and manually curated by PharmGKB. The information listed is provided for educational purposes only and does not constitute an endorsement of any listed test or manufacturer.

A more complete listing of genetic tests is found at the Genetic Testing Registry (GTR).

PGx Test Variants Assayed Related Drugs?
HLA-B*5701 Test rs2395029 , HLA-B*5701
HLA-B*5801 Typing (Allopurinol hypersensitivity) HLA-B*58:01:01 , rs9263726
HLA-B*5801 for Allopurinol Induced Stevens-Johnson Syndrome Risk HLA-B*58:01:01 , rs9263726
Identification of drug hypersensitivity related HLA genes, Including HLA-B*5801 with Allopurinol HLA-B*58:01:01 , rs9263726
Pharmigene HLA-B*5801 Detection HLA-B*58:01:01 , rs9263726
HLA-B*1502 Carbamazepine Sensitivity rs3909184 , rs2844682 , HLA-B*1502

The table below contains information about pharmacogenomic variants on PharmGKB. Please follow the link in the "Variant" column for more information about a particular variant. Each link in the "Variant" column leads to the corresponding PharmGKB Variant Page. The Variant Page contains summary data, including PharmGKB manually curated information about variant-drug pairs based on individual PubMed publications. The PMIDs for these PubMed publications can be found on the Variant Page.

The tags in the first column of the table indicate what type of information can be found on the corresponding Variant Page on the appropriate tab.

Links in the "Drugs" column lead to PharmGKB Drug Pages.

Variant?
(138)
Alternate Names / Tag SNPs ? Drugs ? Alleles ?
(+ chr strand)
Function ? Amino Acid?
Translation
No VIP available CA VA *13:01:01 N/A N/A N/A
No VIP available No VIP available VA *15:01:01:01 N/A N/A N/A
No VIP available CA VA *15:02:01 N/A N/A N/A
No VIP available No VIP available VA *15:11:01 N/A N/A N/A
No VIP available No VIP available VA *37:01:01 N/A N/A N/A
No VIP available CA VA *40:01:01 N/A N/A N/A
No VIP available No VIP available VA *46:01:01 N/A N/A N/A
No VIP available CA VA *51:01:01 N/A N/A N/A
No VIP available No VIP available VA *51:02:01 N/A N/A N/A
No VIP available No VIP available VA *54:01:01 N/A N/A N/A
No VIP available CA VA *57:01:01 N/A N/A N/A
No VIP available CA VA *58:01:01 N/A N/A N/A
Alleles, Functions, and Amino Acid Translations are all sourced from dbSNP 138

Overview

Alternate Names:  None
Alternate Symbols:  None
PharmGKB Accession Id: PA35056

Details

Cytogenetic Location: chr6 : p21.33 - p21.33
GP mRNA Boundary: chr6 : 31321649 - 31324989
GP Gene Boundary: chr6 : 31318649 - 31334989
Strand: minus
The mRNA boundaries are calculated using the gene's default feature set from NCBI, mapped onto the UCSC Golden Path. PharmGKB sets gene boundaries by expanding the mRNA boundaries by no less than 10,000 bases upstream (5') and 3,000 bases downstream (3') to allow for potential regulatory regions.

Haplotype Overview

Source of these HLA allele names: http://hla.alleles.org/ (HLA Informatics Group 1995-2012)

References:

  • [Article:21071412] Robinson J, Mistry K, McWilliam H, Lopez R, Parham P, Marsh SGE: The IMGT/HLA database. Nucleic Acids Research. 2011 39 Suppl 1:D1171-6.
  • [Article:10777106] Robinson J, Malik A, Parham P, Bodmer JG, Marsh SGE: IMGT/HLA - a sequence database for the human major histocompatibility complex. Tissue Antigens. 2000 55:280-7.
  • [Article:20356336] SGE Marsh, ED Albert, WF Bodmer, RE Bontrop, B Dupont, HA Erlich, M Fernández-Vina, DE Geraghty, R Holdsworth, CK Hurley, M Lau, KW Lee, B Mach, WR Mayr, M Maiers, CR Müller, P Parham, EW Petersdorf, T Sasazuki, JL Strominger, A Svejgaard, PI Terasaki, JM Tiercy, J Trowsdale: Nomenclature for factors of the HLA system, 2010. Tissue Antigens 2010 75:291-455.

Source: PharmGKB

All alleles in the download file are on the positive chromosomal strand. PharmGKB considers the first haplotype listed in each table as the reference haplotype for that set.

PharmGKB Curated Pathways

Pathways created internally by PharmGKB based primarily on literature evidence.

PharmGKB contains no curated pathways for this gene. If you would like to volunteer to work on a pathway, please let us know.

External Pathways

Links to non-PharmGKB pathways.

  1. Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell - (Reactome via Pathway Interaction Database)
No related genes are available

Curated Information ?

Evidence Drug Class
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
antiepileptics

Curated Information ?

Publications related to HLA-B: 92

No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Fine Mapping Seronegative and Seropositive Rheumatoid Arthritis to Shared and Distinct HLA Alleles by Adjusting for the Effects of Heterogeneity. American journal of human genetics. 2014. Han Buhm, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
HLA alleles and hypersensitivity to carbamazepine: an updated systematic review with meta-analysis. Pharmacogenetics and genomics. 2013. Grover Sandeep, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Specific HLA types are associated with antiepileptic drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Japanese subjects. Pharmacogenomics. 2013. Kaniwa Nahoko, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
A weighted genetic risk score using all known susceptibility variants to estimate rheumatoid arthritis risk. Annals of the rheumatic diseases. 2013. Yarwood Annie, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
HLA-B*13:01 and the dapsone hypersensitivity syndrome. The New England journal of medicine. 2013. Zhang F-R, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
HLA-B*58:01 is a risk factor for allopurinol-induced DRESS and Stevens-Johnson syndrome/toxic epidermal necrolysis in a Portuguese population. The British journal of dermatology. 2013. Gonçalo M, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
HLA-B*58:01 strongly associates with allopurinol-induced adverse drug reactions in a Japanese sample population. Journal of dermatological science. 2013. Niihara Hiroyuki, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
HLA-A*31:01 and HLA-B*15:02 as Genetic Markers for Carbamazepine Hypersensitivity in Children. Clinical pharmacology and therapeutics. 2013. Amstutz U, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
HLA-B alleles associated with severe cutaneous reactions to antiepileptic drugs in Han Chinese. Epilepsia. 2013. Cheung Ying-Kit, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for HLA-B Genotype and Carbamazepine Dosing. Clinical pharmacology and therapeutics. 2013. Leckband Susan G, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
HLA-B*5801 should be used to screen for risk of Stevens-Johnson syndrome in family members of Han Chinese patients commencing allopurinol therapy. The Journal of rheumatology. 2013. Lee Ming-Han Hugo, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Allopurinol-induced drug rash with eosinophilia and systemic symptoms mimicking acute generalized exanthematous pustulosis. The Journal of dermatology. 2012. Huang Yu Chen, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Human leukocyte antigens (HLA) associated drug hypersensitivity: consequences of drug binding to HLA. Allergy. 2012. Yun J, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
HLA Genotype and Carbamazepine-Induced Cutaneous Adverse Drug Reactions: A Systematic Review. Clinical pharmacology and therapeutics. 2012. Yip V L, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Cutaneous adverse drug reactions to allopurinol: 10 year observational survey of the dermatology department--Cagliari University (Italy). Journal of the European Academy of Dermatology and Venereology : JEADV. 2012. Atzori L, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenomics in clinical practice and drug development. Nature biotechnology. 2012. Harper Andrew R, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis care & research. 2012. Khanna Dinesh, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Clinical Pharmacogenetics Implementation Consortium Guidelines for Human Leukocyte Antigen-B Genotype and Allopurinol Dosing. Clinical pharmacology and therapeutics. 2012. Hershfield M S, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Potential effect of pharmacogenetics on maternal, fetal and infant antiretroviral drug exposure during pregnancy and breastfeeding. Pharmacogenomics. 2012. Olagunju Adeniyi, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Predictive Genetic Testing for Drug-Induced Liver Injury: Considerations of Clinical Utility. Clinical pharmacology and therapeutics. 2012. Alfirevic A, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
HLA-B*58:01 allele is associated with augmented risk for both mild and severe cutaneous adverse reactions induced by allopurinol in Han Chinese. Pharmacogenomics. 2012. Cao Zhi-Hao, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Association between HLA-B*58:01 allele and severe cutaneous adverse reactions with allopurinol in Han Chinese in Hong Kong. The British journal of dermatology. 2012. Chiu M L S, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Genetic and immune predictors for hypersensitivity syndrome to antiepileptic drugs. Translational research : the journal of laboratory and clinical medicine. 2012. Neuman Manuela G, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Clinical Pharmacogenetics Implementation Consortium Guidelines for HLA-B Genotype and Abacavir Dosing. Clinical pharmacology and therapeutics. 2012. Martin M A, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Human leukocyte antigen (HLA) and pharmacogenetics: screening for HLA-B*57:01 among human immunodeficiency virus-positive patients from southern Alberta. Human immunology. 2012. Berka Noureddine, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Drug hypersensitivity and human leukocyte antigens of the major histocompatibility complex. Annual review of pharmacology and toxicology. 2012. Bharadwaj Mandvi, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Allopurinol pharmacogenetics: assessment of potential clinical usefulness. Pharmacogenomics. 2011. Zineh Issam, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
A whole-genome association study of major determinants for allopurinol-related Stevens-Johnson syndrome and toxic epidermal necrolysis in Japanese patients. The pharmacogenomics journal. 2011. Tohkin M, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
A study of HLA class I and class II 4-digit allele level in Stevens-Johnson syndrome and toxic epidermal necrolysis. International journal of immunogenetics. 2011. Cristallo A F, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Initiating allopurinol therapy: do we need to know the patient's HLA status?. Internal medicine journal. 2011. Lee Ming-Han H, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Genome-Wide Association study of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in Europe. Orphanet journal of rare diseases. 2011. Genin Emmanuelle, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
PharmGKB summary: carbamazepine pathway. Pharmacogenetics and genomics. 2011. Thorn Caroline F, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Prospective-retrospective biomarker analysis for regulatory consideration: white paper from the industry pharmacogenomics working group. Pharmacogenomics. 2011. Patterson Scott D, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenomics: the genetics of variable drug responses. Circulation. 2011. Roden Dan M, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Association of the genetic marker for abacavir hypersensitivity HLA-B*5701 with HCP5 rs2395029 in Mexican Mestizos. Pharmacogenomics. 2011. Sanchez-Giron Francisco, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenetics: From Bench to Byte- An Update of Guidelines. Clinical pharmacology and therapeutics. 2011. Swen J J, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
HLA-B58 can help the clinical decision on starting allopurinol in patients with chronic renal insufficiency. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association. 2011. Jung Jae-Woo, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Carbamazepine-induced toxic effects and HLA-B*1502 screening in Taiwan. The New England journal of medicine. 2011. Chen Pei, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Genomics and drug response. The New England journal of medicine. 2011. Wang Liewei, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
HLA-B*1502 genotyping in two Chinese patients with phenytoin-induced Stevens-Johnson syndrome. Epilepsy & behavior : E&B. 2011. Min Fu-Li, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Positive and negative associations of HLA class I alleles with allopurinol-induced SCARs in Koreans. Pharmacogenetics and genomics. 2011. Kang Hye-Ryun, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Phenytoin-induced Stevens-Johnson syndrome with negative HLA-B*1502 allele in mainland China: Two cases. Seizure : the journal of the British Epilepsy Association. 2011. Hu Fa-Yun, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Practical recommendations for pharmacogenomics-based prescription: 2010 ESF-UB Conference on Pharmacogenetics and Pharmacogenomics. Pharmacogenomics. 2011. Becquemont Laurent, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Association of HLA-B*5801 allele and allopurinol-induced Stevens Johnson syndrome and toxic epidermal necrolysis: a systematic review and meta-analysis. BMC medical genetics. 2011. Somkrua Ratchadaporn, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Breaking Barriers in the Genomics and Pharmacogenetics of Drug Addiction. Clinical pharmacology and therapeutics. 2010. Ho M K, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Systematic review of pharmacoeconomic studies of pharmacogenomic tests. Pharmacogenomics. 2010. Beaulieu Mathieu, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Characterization of 107 genomic DNA reference materials for CYP2D6, CYP2C19, CYP2C9, VKORC1, and UGT1A1: a GeT-RM and Association for Molecular Pathology collaborative project. The Journal of molecular diagnostics : JMD. 2010. Pratt Victoria M, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Drug-induced liver injury: past, present and future. Pharmacogenomics. 2010. Daly Ann K. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Common risk allele in aromatic antiepileptic-drug induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Han Chinese. Pharmacogenomics. 2010. Hung Shuen-Iu, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Genetic determinants of HIV-1 infection and progression to AIDS: immune response genes. Tissue antigens. 2009. Kaur G, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
HLA-B27 and HLA-B51 determination in Tunisian healthy subjects and patients with suspected ankylosing spondylitis and Behçet's disease. Annals of the New York Academy of Sciences. 2009. Sakly Nabil, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Strong association between HLA-B*5801 and allopurinol-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in a Thai population. Pharmacogenetics and genomics. 2009. Tassaneeyakul Wichittra, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
HLA B27 as predisposition factor to suffer age related macular degeneration. Cellular & molecular immunology. 2009. Villegas Becerril Enrique, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Multiple Loci within the major histocompatibility complex confer risk of psoriasis. PLoS genetics. 2009. Feng Bing-Jian, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Human leukocyte antigen frequency in human high-grade gliomas: a case-control study in Sicily. Neurosurgery. 2009. La Torre Domenico, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Human leukocyte antigen-related risk factors for toxic epidermal necrosis. The Pediatric infectious disease journal. 2009. Kemen Christoph, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
HLA-B is the best candidate of susceptibility genes in HLA for Japanese ulcerative colitis. Tissue antigens. 2009. Aizawa H, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Epilepsy pharmacogenetics. Pharmacogenomics. 2009. Kasperavici¿te Dalia, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Confirmation of HLA class II independent type 1 diabetes associations in the major histocompatibility complex including HLA-B and HLA-A. Diabetes, obesity & metabolism. 2009. Howson J M M, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
HLA-B*3505 allele is a strong predictor for nevirapine-induced skin adverse drug reactions in HIV-infected Thai patients. Pharmacogenetics and genomics. 2009. Chantarangsu Soranun, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Genome-wide approaches to identify pharmacogenetic contributions to adverse drug reactions. The pharmacogenomics journal. 2009. Nelson M R, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
The clinical impact of pharmacogenetics on the treatment of epilepsy. Epilepsia. 2009. Löscher Wolfgang, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Carbamazepine and phenytoin induced Stevens-Johnson syndrome is associated with HLA-B*1502 allele in Thai population. Epilepsia. 2008. Locharernkul Chaichon, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Evolution and selection of human leukocyte antigen alleles by Plasmodium falciparum infection. Human immunology. 2008. Ghosh Kanjaksha. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
FDA: Epilepsy drugs may carry skin risks for Asians. JAMA : the journal of the American Medical Association. 2008. Kuehn Bridget M. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
HLA-B locus in Japanese patients with anti-epileptics and allopurinol-related Stevens-Johnson syndrome and toxic epidermal necrolysis. Pharmacogenomics. 2008. Kaniwa Nahoko, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Carbamazepine, HLA-B*1502 and risk of Stevens-Johnson syndrome and toxic epidermal necrolysis: US FDA recommendations. Pharmacogenomics. 2008. Ferrell P Brent, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Genetic variation in drug transporters in ethnic populations. Clinical pharmacology and therapeutics. 2008. Cropp C D, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
The HCP5 single-nucleotide polymorphism: a simple screening tool for prediction of hypersensitivity reaction to abacavir. The Journal of infectious diseases. 2008. Colombo Sara, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
A European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs. Pharmacogenetics and genomics. 2008. Lonjou Christine, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenetic information derived from analysis of HLA alleles. Pharmacogenomics. 2008. Gatanaga Hiroyuki, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
HLA-B*5701 screening for hypersensitivity to abacavir. The New England journal of medicine. 2008. Mallal Simon, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Ticlopidine-induced hepatotoxicity is associated with specific human leukocyte antigen genomic subtypes in Japanese patients: a preliminary case-control study. The pharmacogenomics journal. 2008. Hirata K, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
HLA-B*5701 clinical testing: early experience in the United States. Pharmacogenetics and genomics. 2007. Faruki Hawazin, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
[Study on correlation between HLA-A, B, DR alleles and Duchenne muscular dystrophy]. Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics. 2007. Chen Wei, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Human leukocyte antigens and drug hypersensitivity. Current opinion in allergy and clinical immunology. 2007. Chung Wen-Hung, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
A whole-genome association study of major determinants for host control of HIV-1. Science (New York, N.Y.). 2007. Fellay Jacques, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Association between HLA-B*1502 allele and antiepileptic drug-induced cutaneous reactions in Han Chinese. Epilepsia. 2007. Man Celeste B L, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Stevens-Johnson syndrome, drug-induced hypersensitivity syndrome and toxic epidermal necrolysis caused by allopurinol in patients with a common HLA allele: what causes the diversity?. Dermatology (Basel, Switzerland). 2007. Dainichi Teruki, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
HLA-B locus in Caucasian patients with carbamazepine hypersensitivity. Pharmacogenomics. 2006. Alfirevic Ana, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
[Disequilibrium linkage between the polymorphism in exons 2, 3 and 4 of the MICA gene and HLA-B antigen of patient with ankylosing spondylitis]. Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics. 2006. Su Hong, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions. Pharmacogenetics and genomics. 2006. Hung Shuen-Iu, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
A marker for Stevens-Johnson syndrome ...: ethnicity matters. The pharmacogenomics journal. 2006. Lonjou C, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Overview of the pharmacogenetics of HIV therapy. The pharmacogenomics journal. 2006. Rodríguez-Nóvoa S, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
[Correlation between the polymorphism of HLA-A, -B, and -DRB1 alleles and susceptibility to leukemia]. Xi bao yu fen zi mian yi xue za zhi = Chinese journal of cellular and molecular immunology. 2005. Zhou Lan-xia, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proceedings of the National Academy of Sciences of the United States of America. 2005. Hung Shuen-Iu, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Cost-effectiveness analysis of HLA B*5701 genotyping in preventing abacavir hypersensitivity. Pharmacogenetics. 2004. Hughes Dyfrig A, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Medical genetics: a marker for Stevens-Johnson syndrome. Nature. 2004. Chung Wen-Hung, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet. 2002. Mallal S, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
The lower susceptibility to Plasmodium falciparum malaria of Fulani of Burkina Faso (west Africa) is associated with low frequencies of classic malaria-resistance genes. Transactions of the Royal Society of Tropical Medicine and Hygiene. 2001. Modiano D, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Common west African HLA antigens are associated with protection from severe malaria. Nature. 1991. Hill A V, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
HLA typing in birdshot chorioretinopathy. American journal of ophthalmology. 1988. Priem H A, et al. PubMed